Shanmai Guo,
Xi Guan 
For correspondence:- Xi Guan Email: x_guan0712@163.com Tel:+86051988132619
Accepted: 19 December 2022 Published: 30 January 2023
Citation: Guo S, Guan X. Eriocalyxin B relieves kidney damage in a rat model of membranous nephropathy by inhibiting JAK/STAT3 pathway. Trop J Pharm Res 2023; 22(1):67-72 doi: 10.4314/tjpr.v22i1.10
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the function of eriocalyxin B (EriB) in membranous nephropathy (MN) in a rat model and the related mechanisms.
Methods: Cationic C-BSA was injected into Sprague-Dawley (SD) rats to generate a rat model of MN. The MN rats were treated with different concentrations of EriB (2.5, 5, and 10 mg/kg). After treatment, their kidneys were excised, sectioned, and hematoxylin and eosin (H&E) stained to determine renal injury, while Masson's trichrome staining was performed to determine renal tissue fibrosis. Bradford assay was used to determine rat proteinuria and ELISA employed to determine blood urea nitrogen (BUN) and serum creatinine (SCr) levels. ELISA was also used to measure IL-1β, IL-6, and TGF-α levels, while immunoblot analysis was used to assess protein ex
Results: Compared with sham rats, MN rats showed increased the contents of proteinuria, BUN, and SCr (p < 0.01), induced serious renal injury, and increased ex
Conclusion: EriB alleviates renal injury in MN rats by inhibiting JAK/STAT3 pathway. Thus, EriB is a potential drug for the management of MN.
Archives
News Updates
Fulltext in PDF